ARS Pharmaceuticals Inc
SPRY16.927USD
-0.523-3.00%
交易中 （美東）報價延遲15分鐘
1.66B總市值
207.68本益比TTM
關於 ARS Pharmaceuticals Inc 公司
ARS Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於開發 neffy，用於緊急治療 I 型過敏反應，包括過敏反應。neffy 是一種專有的腎上腺素組合物，含有一種名爲 Intravail 的吸收促進劑，可使 neffy 以小劑量、小劑量和鼻腔噴霧的形式提供類似注射的腎上腺素吸收。I 型過敏反應是可能危及生命的超敏反應，可能在接觸過敏原幾分鐘內發生，需要立即治療以緩解症狀並防止進一步發展。
公司簡介
公司代碼SPRY
公司名稱ARS Pharmaceuticals Inc
上市日期Dec 04, 2020
成立日期2016
CEOMr. Richard E. Lowenthal
員工數量155
證券類型Ordinary Share
年結日Dec 04
公司地址11682 El Camino Real, Suite 120
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92130
電話18587719307
網址https://ars-pharma.com/
公司代碼SPRY
上市日期Dec 04, 2020
成立日期2016
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月2日 週一
更新時間: 6月2日 週一
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
持股股東
持股股東
佔比
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
20.71%
Hedge Fund
19.64%
Venture Capital
15.20%
Investment Advisor
13.88%
Individual Investor
12.16%
Private Equity
8.44%
Corporation
4.91%
Research Firm
2.18%
Pension Fund
0.27%
Other
2.62%
機構持股
更新時間: 10 小時前
更新時間: 10 小時前
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
361
95.98M
97.72%
-8.84M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
2023Q1
271
88.79M
98.08%
+1.91M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
10.86M
11.06%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
10.51M
10.71%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.44%
--
--
Mar 31, 2025
Lowenthal (Richard E)
6.83M
6.95%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.91%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.66%
-556.66K
-10.85%
Mar 31, 2025
SR One Capital Management, LP
4.01M
4.09%
--
--
Mar 31, 2025
AllianceBernstein L.P.
3.92M
3.99%
+42.07K
+1.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.88M
3.95%
-275.85K
-6.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
3.54%
+23.34K
+0.68%
Mar 31, 2025
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
First Trust Small Cap Growth AlphaDEX Fund
0.6%
Janus Henderson Small Cap Growth Alpha ETF
0.39%
First Trust Small Cap Core Alphadex Fund
0.29%
SPDR S&P Biotech ETF
0.24%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
First Trust Multicap Growth Alphadex Fund
0.11%
Principal U.S. Small-Cap ETF
0.11%
查看更多
First Trust Small Cap Growth AlphaDEX Fund
佔比0.6%
Janus Henderson Small Cap Growth Alpha ETF
佔比0.39%
First Trust Small Cap Core Alphadex Fund
佔比0.29%
SPDR S&P Biotech ETF
佔比0.24%
iShares Micro-Cap ETF
佔比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.16%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
First Trust Multicap Growth Alphadex Fund
佔比0.11%
Principal U.S. Small-Cap ETF
佔比0.11%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
